The recommendations will provide an important tool to help improve the quality of the diagnostic process, so patients receive an early and accurate diagnosis.
Jenna Payesko
Advertisement
Articles by Jenna Payesko
The FDA has accepted a biologics license application for galcanezumab as a prophylactic treatment for migraines.
Advertisement
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players
2
Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia
3
This Week on NeurologyLive® — September 7, 2026
4
FDA Action Update, August 2026: Approvals, Clearances, and Designations
5